Wockhardt Limited — PPTs, 04-06-2026: Investor Presentation

1. Business Performance:

Wockhardt delivered robust FY26 performance with total income hitting INR 3,373 Cr and EBITDA soaring 51% YoY to INR 630 Cr! PBT reached INR 238 Cr. Profitability improved significantly, with EBITDA margin climbing to 18.6% from 5.4%. Specialty business (novel antibiotics, biosimilars) contributed 23% to revenues, with Emrok sales jumping ~50%. Emerging Markets saw a strong 35% growth.

2. Growth Drivers or Strategy:

The company is focused on accelerating growth and achieving sustainable operational excellence, leveraging AI. Key strategic drivers include the global launch of their novel antibiotic Zaynich, enhancing biotech capacity for insulin biosimilars, and strengthening pharma businesses in EU and India.

3. Recent Developments:

Huge news: Zaynich, an Indian-discovered novel antibiotic, secured crucial approvals from both the US FDA and India's CDSCO, paving the way for its global launch. Production of Human Insulin and Glargine biosimilars has also significantly scaled up.

4. Key Financial Metrics:

FY26 Income: INR 3,373 Cr. | FY26 EBITDA: INR 630 Cr. | FY26 PBT: INR 238 Cr. | Cash & Equivalents: INR 662 Cr. | Net Debt:Equity: 0.10.

5. Management Commentary / Outlook:

Management's vision for the next two years emphasizes accelerated growth and sustainable operational excellence. They are laser-focused on a patient-centric approach for Zaynich, especially in Emerging Markets, aiming to address millions suffering from carbapenem-resistant infections and generate substantial, sustainable revenue.